MINYANVILLE ORIGINAL Gilead Sciences (NASDAQ:GILD) took another step forward with its hepatitis C drug program Tuesday showing a strong cure rate for hard-to-treat patients in a late-stage study. The data met Wall Street expectations and is significant because it is the first of several trials in the final round -- or so-called Phase III stage -- of study necessary to win US approval. The company is expected to announce three more Phase III trial results in the first quarter of 2013 and will likely file for US Food and Drug Administration approval for its drug sofosbuvir by the middle ...